Sera Prognostics, Inc.

Sera Prognostics, Inc.

SERA·NASDAQ

$2.25

+9.5%
HealthcareMedical - Diagnostics & Research

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

At a Glance

Live Snapshot
Market Cap$85.74M
EPS-0.6700
P/E Ratio-3.35
Earnings Date08/05/2026

sera

Account Payables

Last Annual Value

862.00K

3-Year CAGR

-18%

5-Year CAGR

14%

10-Year CAGR

1%

Sera Prognostics, Inc.

Sera Prognostics, Inc. Competitors Analysis of Account Payables

SERA · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
862.00K
-6.2%-6.4%N/A 
4.14M
28.0%1.0%N/A
3.06M
4.1%3.1%6.7%
2.53M
2.1%6.8%N/A
DCGO logo
DocGo Inc.
NASDAQ:DCGO
11.11M
-17.6%-6.8%N/A
1.96M
-19.2%-22.8%8.6%
2.54M
38.7%7.0%19.7%
653.00K
-35.8%-4.9%-3.5%
921.00K
-16.6%-4.1%-1.4%
970.00K
-5.4%-8.2%N/A
0.00
N/AN/AN/A
Sera Prognostics, Inc.

Sera Prognostics, Inc. Fair Value Envelope

SERA · NASDAQ

Our analysis suggests that SERA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $2.245, this represents a potential HIDDEN relative to our calculated worth for Sera Prognostics, Inc..

Intrinsic Value
Current Price: $2.245